Related Experiment Video

Updated: May 8, 2026

Screening Ion Channels in Cancer Cells
06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Targeting receptor tyrosine kinases in solid tumors

Jianliang Zhang1, Steven N Hochwald

  • 1Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.

Surgical Oncology Clinics of North America
|September 10, 2013
PubMed

Insights

Tyrosine kinase (TK) inhibitors offer targeted cancer therapy by blocking tumor growth signals. This review covers current TK inhibitors for solid tumors and explores future therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinase (TK) cascades are crucial in tumorigenesis, regulating cell growth, differentiation, and motility.
  • Targeted drug development focuses on inhibiting cancer-associated signal transduction pathways.
  • TK inhibitors offer potential for treating local and metastatic solid tumors with improved selectivity and reduced toxicity.

Purpose of the Study:

  • To review tyrosine kinase signaling in solid tumors.
  • To evaluate properties of approved TK-inhibitor drugs.
  • To identify potential TK pathways for future cancer therapies.

Main Methods:

  • Literature review of solid tumor-related TK signaling.
  • Analysis of clinical applications of receptor TK pathways.
  • Assessment of recently approved TK-inhibitor drugs.
  • Exploration of potential future therapeutic targets.

Main Results:

  • TK pathways are integral to all phases of tumor development.
  • Several receptor TK pathways have been successfully translated into clinical treatments.
  • Recently approved TK inhibitors demonstrate efficacy in treating solid tumors.
  • Emerging TK pathways present opportunities for novel therapeutic interventions.

Conclusions:

  • Targeted inhibition of TK signaling is a key strategy in modern oncology.
  • Approved TK inhibitors provide valuable treatment options for solid tumors.
  • Further research into novel TK pathways holds promise for advancing cancer therapy.
Keywords:
CancerSolid tumorsTyrosine kinase inhibitors

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...